Bladder cancer accounts for nearly 170,000 deaths worldwide annually. For over 4 decades,
the systemic management of muscle‐invasive and advanced bladder cancer has primarily …

Antibody–drug conjugates (ADCs) are a relatively new class of anticancer agents designed
to merge the selectivity of monoclonal antibodies with cell killing properties of …

PURPOSE Patients with metastatic urothelial carcinoma (mUC) who progress on platinum-
based combination chemotherapy (PLT) and checkpoint inhibitors (CPIs) have limited …

Background Sacituzumab govitecan (SG), a trophoblast cell surface antigen-2 (Trop-2)-
directed antibody-drug conjugate, has demonstrated antitumor efficacy and acceptable …

Background Erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase
inhibitor, was shown to be clinically active and tolerable in patients with advanced urothelial …

Sacituzumab govitecan (sacituzumab govitecan-hziy; Trodelvy™) is a Trop-2-directed
antibody conjugated to a topoisomerase I inhibitor (SN-38) that is being developed by …

Trop2 is a transmembrane glycoprotein and calcium signal transducer with limited
expression in normal human tissues. It is consistently overexpressed in a variety of …

Introduction We describe a new, third-generation of antibody-drug conjugates (ADCs)
having a high drug payload against topoisomerase I, important for DNA function, and …

Urothelial carcinoma (UC) is a frequent cause of cancer-related deaths worldwide.
Metastatic UC has been historically associated with poor prognosis, with a median overall …

Antibody-drug conjugates (ADCs) that exploit the active metabolite SN-38, which is derived
from the popular anticancer drug, irinotecan (a camptothecin that inhibits the nuclear …